孟坦因在限制大鼠耳毒性的作用
Pavlos Pavlidis1,2, Vasilis Spyridon Tseriotis2, Kyriaki Papadopoulou3
1Department of Otorhinolarhingology / Head & Neck Surgery, University Medical Center Mainz, Mainz, Germany.
概括
孟曼丁是一种NMDA-对抗剂,可以防止阿米卡辛诱导的听力损失. 在老鼠中与阿米卡辛治疗同时或之后给予美曼丁,可减少耳损伤并保持耳活动.
科学领域:
- 耳部毒理学 耳部毒理学
- 神经药理学神经药理学
- 审计科学 审计科学
背景情况:
- 艾米卡辛是一种氨基糖类抗生素,具有已知的耳毒性副作用.
- 耳毒性,特别是听力损失,是阿米卡辛治疗的一个重要问题.
- 目前正在研究NMDA受体对抗剂是否具有神经保护性.
研究的目的:
- 评估孟坦丁对阿米卡辛诱导的耳中毒性的保护作用.
- 为了确定记忆素的时间 (同时或连续) 是否会影响其保护功效.
- 评估阿米卡辛和记忆素联合治疗对耳功能和结构的影响.
主要方法:
- 40只Wistar大鼠被分为四组:对照组,仅使用阿米卡辛,阿米卡辛+记忆剂,以及阿米卡辛后续使用记忆剂.
- 艾米卡辛 (200毫克/千克) 和美曼丁 (10毫克/千克) 用于腹膜内注射.
- 扭曲产品耳声发射 (DPOAE) 用于评估耳活动.
- 在耳组织上进行了组织学和免疫组织化学分析.
主要成果:
- 阿米卡辛治疗导致耳活动下降,由减少的DPOAE振幅证明.
- 在仅服用阿米卡辛的组中观察到DPOAE最明显的减少.
- 组织学检查显示,在与阿米卡辛同时或之后接受记忆剂治疗的老鼠中,耳损伤不太严重.
结论:
- 孟曼丁在老鼠中显示出对阿米卡辛诱导的耳毒性有保护作用.
- 同时或连续地给予美曼丁可以部分恢复耳结构和功能.
- 这些发现表明一种潜在的治疗策略,以减轻阿米卡辛的耳毒作用.
更多相关视频
09:06Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
Published on: January 9, 2019
13.9K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179